Counterpoint: Were industry-sponsored rofl umilast trials appropriate

Chest

Volumn 145, Issue 5, 2014, Pages 939-942

  Rho, Jason ^a   Ho, Nancy ^b   Prasad, Vinay ^c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; ROFLUMILAST;

CHRONIC OBSTRUCTIVE LUNG DISEASE; DIARRHEA; DISEASE SEVERITY; DRUG APPROVAL; DRUG EFFICACY; DRUG INDUSTRY; DRUG RESEARCH; FOOD AND DRUG ADMINISTRATION; HUMAN; NOTE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS;

ALBUTEROL; AMINOPYRIDINES; ANTI-INFLAMMATORY AGENTS; BENZAMIDES; BRONCHODILATOR AGENTS; FEMALE; HUMANS; MALE; PHOSPHODIESTERASE 4 INHIBITORS; PHOSPHODIESTERASE INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SCOPOLAMINE DERIVATIVES;

EID: 84899832989     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.14-0114     Document Type: Note

References (25)

1. Ioannidis JP . Mega-trials for blockbusters. JAMA . 2013; 309(3): 239-240.
2. Nycomed's novel COPD therapy rofl umilast receives FDA approval. WorldPharmaNews website. http://www.worldphar manews.com/nycomed/1600-nycomeds- novel-copd-therapy-rofl umilast-receives-fda-approval . Accessed March 13, 2012.
3. Forest Laboratories management discusses Q3 2012 resultsearnings call transcript 2012. Seeking Alpha website. http://seekingalpha.com/article/320088- forest-laboratories-management-discusses-q3-2012-results-earnings-call- transcript ? part 5 single . Accessed October 2, 2012.
4. Rabe KF , Bateman ED , O'Donnell D , Witte S , Bredenbroker D , Bethke TD . Rofl umilast-an oral anti-infl ammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial . Lancet . 2005 ; 366 (9485): 563-571.
5. Bergmann JF . Rofl umilast for chronic obstructive pulmonary disease . Lancet . 2005 ; 366 (9500): 1845.
6. Vassiliou V . Rofl umilast for chronic obstructive pulmonary disease . Lancet . 2005 ; 366 (9500): 1846.
7. Gupta S . Side-effects of rofl umilast . Lancet . 2012 ; 379 (9817): 710-711.
8. US Department of Health and Human Services . Pulmonary-Allergy Drugs Advisory Committee meeting on rofl umilast. US Food and Drug Administration website. http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/UCM 212606 .pdf . Accessed March 4, 2013.
9. Calverley PM , Anderson JA , Celli B , et al ; TORCH investigators . Salmeterol and fl uticasone propionate and survival in chronic obstructive pulmonary disease . N Engl J Med . 2007 ; 356 (8): 775-789.
10. Tashkin DP , Celli B , Senn S , et al ; UPLIFT Study Investigators . A 4-year trial of tiotropium in chronic obstructive pulmonary disease . N Engl J Med . 2008 ; 359 (15): 1543-1554.
11. Calverley PM , Rabe KF , Goehring UM , Kristiansen S , Fabbri LM , Martinez FJ ; M2-124 and M2-125 study groups . Rofl umilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials . Lancet . 2009 ; 374 (9691): 685-694.
12. Center for Drug Evaluation and Research. Application number 022522Orig1s000: medical review(s). US Food and Drug Administration website. http://www.accessdata . fda .gov/drugs atfda-docs/nda/2011/022522Orig1s000MedR. pdf . Accessed March 14, 2011.
13. Fabbri LM , Calverley PM , Izquierdo-Alonso JL , et al ; M2-127 and M2-128 study groups . Rofl umilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials . Lancet . 2009 ; 374 (9691): 695-703.
14. Suissa S , Barnes PJ . Inhaled corticosteroids in COPD: the case against . Eur Respir J. 2009 ; 34 (1): 13-16.
15. Suissa S , Ernst P , Vandemheen KL , Aaron SD . Methodological issues in therapeutic trials of COPD . Eur Respir J. 2008 ; 31 (5): 927-933.
16. NDA No. 022522 drug label. http://www.accessdata . fda .gov/drugsatfda-docs/appletter/2011/022522s000ltr .pdf . Accessed March 15, 2012.
17. Barnes PJ . Chronic obstructive pulmonary disease: a grow ing but neglected global epidemic . PLoS Med . 2007 ; 4 (5): e112.
18. Bekelman JE , Li Y , Gross CP . Scope and impact of fi nancial confl icts of interest in biomedical research: a systematic review . JAMA . 2003 ; 289 (4): 454-465.
19. Lexchin J , Bero LA , Djulbegovic B , Clark O . Pharmaceutical industry sponsorship and research outcome and quality: systematic review . BMJ . 2003 ; 326 (7400): 1167-1170.
20. Djulbegovic B , Lacevic M , Cantor A , et al . The uncertainty principle and industry-sponsored research . Lancet . 2000 ; 356 (9230): 635-638.
21. Cho MK , Bero LA . The quality of drug studies published in symposium proceedings . Ann Intern Med . 1996 ; 124 (5): 485-489.
22. Kjaergard LL , Nikolova D , Gluud C . Randomized clinical trials in HEPATOLOGY: predictors of quality . Hepatology . 1999 ; 30 (5): 1134-1138.
23. Knox KS , Adams JR , Djulbegovic B , Stinson TJ , Tomor C , Bennet CL . Reporting and dissemination of industry versus non-profi t sponsored economic analyses of six novel drugs used in oncology . Ann Oncol . 2000 ; 11 (12): 1591-1595.
24. Jadad AR , Moore RA , Carroll D , et al . Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials . 1996 ; 17 (1): 1-12.
25. Hill KP , Ross JS , Egilman DS , Krumholz HM . The ADVANTAGE seeding trial: a review of internal documentS . Ann Intern Med . 2008 ; 149 (4): 251-258.